Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Optimizing Neuro-Oncology Imaging: A Review of Deep Learning Approaches for Glioma Imaging.

Shaver MM, Kohanteb PA, Chiou C, Bardis MD, Chantaduly C, Bota D, Filippi CG, Weinberg B, Grinband J, Chow DS, Chang PD.

Cancers (Basel). 2019 Jun 14;11(6). pii: E829. doi: 10.3390/cancers11060829. Review.

2.

Chemotherapy-related cognitive dysfunction and effects on quality of life in gynecologic cancer patients.

Pearre DC, Bota DA.

Expert Rev Qual Life Cancer Care. 2018;3(1):19-26. doi: 10.1080/23809000.2018.1443811. Epub 2018 Feb 26.

3.

Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy.

Bisoc A, Ciurescu D, Rădoi M, Tântu MM, Rogozea L, Sweidan AJ, Bota DA.

Am J Ther. 2019 Jan 3. doi: 10.1097/MJT.0000000000000930. [Epub ahead of print]

PMID:
30648987
4.

Somatic SMARCB1 Mutation in Sporadic Multiple Meningiomas: Case Report.

Wang AS, Jamshidi AO, Oh N, Sahyouni R, Nowroozizadeh B, Kim R, Hsu FPK, Bota D.

Front Neurol. 2018 Oct 26;9:919. doi: 10.3389/fneur.2018.00919. eCollection 2018.

5.

Magmas inhibition as a potential treatment strategy in malignant glioma.

Di K, Lomeli N, Bota DA, Das BC.

J Neurooncol. 2019 Jan;141(2):267-276. doi: 10.1007/s11060-018-03040-8. Epub 2018 Nov 9.

PMID:
30414099
6.

Multiscale modeling of glioblastoma.

Yan H, Romero-López M, Benitez LI, Di K, Frieboes HB, Hughes CCW, Bota DA, Lowengrub JS.

Transl Cancer Res. 2018 Feb;7(Suppl 1):S96-S98. doi: 10.21037/tcr.2017.12.10. No abstract available.

7.

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts.

Bota DA, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FP, Schönthal AH, Hofman FM, Chen TC, Zidovetzki R, Pretto C, Strik A, Schijns VE, Stathopoulos A.

CNS Oncol. 2018 Jul 1;7(3):CNS22. doi: 10.2217/cns-2018-0009. Epub 2018 Aug 29.

8.

Therapeutic Immunization against Glioblastoma.

Schijns VEJC, Pretto C, Strik AM, Gloudemans-Rijkers R, Deviller L, Pierre D, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FPK, Hofman FM, Chen TC, Zidovetzki R, Bota DA, Stathopoulos A.

Int J Mol Sci. 2018 Aug 27;19(9). pii: E2540. doi: 10.3390/ijms19092540. Review.

9.

Mineralocorticoid receptor antagonism improves parenchymal arteriole dilation via a TRPV4-dependent mechanism and prevents cognitive dysfunction in hypertension.

Diaz-Otero JM, Yen TC, Fisher C, Bota D, Jackson WF, Dorrance AM.

Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1304-H1315. doi: 10.1152/ajpheart.00207.2018. Epub 2018 Aug 17.

PMID:
30118343
10.

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 Jun 29;16(1):179. doi: 10.1186/s12967-018-1552-1.

11.

CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine Challenges.

Jamieson CHM, Millan MT, Creasey AA, Lomax G, Donohoe ME, Walters MC, Abedi M, Bota DA, Zaia JA, Adams JS.

Cell Stem Cell. 2018 Jun 1;22(6):801-805. doi: 10.1016/j.stem.2018.05.007.

12.

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6. Erratum in: J Transl Med. 2018 Jun 29;16(1):179.

13.

Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas.

Chang P, Grinband J, Weinberg BD, Bardis M, Khy M, Cadena G, Su MY, Cha S, Filippi CG, Bota D, Baldi P, Poisson LM, Jain R, Chow D.

AJNR Am J Neuroradiol. 2018 Jul;39(7):1201-1207. doi: 10.3174/ajnr.A5667. Epub 2018 May 10.

PMID:
29748206
14.

Intracranial meningioma with carcinoma tumor-to-tumor metastasis: two case reports.

Pham JT, Kim RC, Nguyen A, Bota D, Kong XT, Vadera S, Hsu F, Carrillo JA.

CNS Oncol. 2018 Apr;7(2):CNS09. doi: 10.2217/cns-2017-0022. Epub 2018 Apr 26.

15.

Expression of the BRAF L597Q mutation in sporadic neurofibromas of the upper extremity.

Shaterian A, Bota D, Leis A.

Exp Mol Pathol. 2017 Dec;103(3):276-278. doi: 10.1016/j.yexmp.2017.11.010. Epub 2017 Nov 21.

PMID:
29162506
16.

Diminished stress resistance and defective adaptive homeostasis in age-related diseases.

Lomeli N, Bota DA, Davies KJA.

Clin Sci (Lond). 2017 Oct 25;131(21):2573-2599. doi: 10.1042/CS20160982. Print 2017 Nov 1. Review.

17.

Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions.

Chow D, Chang P, Weinberg BD, Bota DA, Grinband J, Filippi CG.

AJR Am J Roentgenol. 2018 Jan;210(1):30-38. doi: 10.2214/AJR.17.18754. Epub 2017 Oct 5. Review.

18.

3D Mathematical Modeling of Glioblastoma Suggests That Transdifferentiated Vascular Endothelial Cells Mediate Resistance to Current Standard-of-Care Therapy.

Yan H, Romero-López M, Benitez LI, Di K, Frieboes HB, Hughes CCW, Bota DA, Lowengrub JS.

Cancer Res. 2017 Aug 1;77(15):4171-4184. doi: 10.1158/0008-5472.CAN-16-3094. Epub 2017 May 23.

19.

Cancer-Incidence, prevalence and mortality in the oldest-old. A comprehensive review.

Nolen SC, Evans MA, Fischer A, Corrada MM, Kawas CH, Bota DA.

Mech Ageing Dev. 2017 Jun;164:113-126. doi: 10.1016/j.mad.2017.05.002. Epub 2017 May 11. Review.

PMID:
28502820
20.

Case of glioblastoma patient treated with tumor treating fields therapy at recurrence degenerating to sarcoma.

Majd P, O'Connell DE, Kim RC, Bota DA, Carrillo JA.

CNS Oncol. 2017 Apr;6(2):89-94. doi: 10.2217/cns-2016-0035. Epub 2017 Mar 17.

21.

First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report.

O'Connell D, Shen V, Loudon W, Bota DA.

CNS Oncol. 2017 Jan;6(1):11-18. doi: 10.2217/cns-2016-0018. Epub 2016 Dec 5.

22.

Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats.

Lomeli N, Di K, Czerniawski J, Guzowski JF, Bota DA.

Free Radic Biol Med. 2017 Jan;102:274-286. doi: 10.1016/j.freeradbiomed.2016.11.046. Epub 2016 Nov 28.

23.

Systemic cisplatin exposure during infancy and adolescence causes impaired cognitive function in adulthood.

John T, Lomeli N, Bota DA.

Behav Brain Res. 2017 Feb 15;319:200-206. doi: 10.1016/j.bbr.2016.11.013. Epub 2016 Nov 13.

24.

Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma.

Di K, Lomeli N, Wood SD, Vanderwal CD, Bota DA.

Oncotarget. 2016 Nov 22;7(47):77457-77467. doi: 10.18632/oncotarget.12681.

25.

A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma.

Trusheim J, Dunbar E, Battiste J, Iwamoto F, Mohile N, Damek D, Bota DA, Connelly J.

CNS Oncol. 2017 Jan;6(1):29-43. doi: 10.2217/cns-2016-0032. Epub 2016 Sep 15. Review.

26.

The effects of sequential treatments on hippocampal volumes in malignant glioma patients.

Nolen SC, Lee B, Shantharam S, Yu HJ, Su L, Billimek J, Bota DA.

J Neurooncol. 2016 Sep;129(3):433-441. doi: 10.1007/s11060-016-2188-8. Epub 2016 Jul 8.

27.

Mitochondrial Lon protease in human disease and aging: Including an etiologic classification of Lon-related diseases and disorders.

Bota DA, Davies KJ.

Free Radic Biol Med. 2016 Nov;100:188-198. doi: 10.1016/j.freeradbiomed.2016.06.031. Epub 2016 Jul 5. Review.

28.

Cognitive Impairment in Survivors of Adolescent and Early Young Adult Onset Non-CNS Cancers: Does Chemotherapy Play a Role?

John TD, Sender LS, Bota DA.

J Adolesc Young Adult Oncol. 2016 Sep;5(3):226-31. doi: 10.1089/jayao.2015.0025. Epub 2016 Apr 14. Review.

PMID:
27078009
29.

Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.

Di K, Lloyd GK, Abraham V, MacLaren A, Burrows FJ, Desjardins A, Trikha M, Bota DA.

Neuro Oncol. 2016 Jun;18(6):840-8. doi: 10.1093/neuonc/nov299. Epub 2015 Dec 17.

30.

Perceptions of Community HIV/STI Risk Among U.S Women Living in Areas with High Poverty and HIV Prevalence Rates.

Blackstock OJ, Frew P, Bota D, Vo-Green L, Parker K, Franks J, Hodder SL, Justman J, Golin CE, Haley DF, Kuo I, Adimora AA, Rompalo A, Soto-Torres L, Wang J, Mannheimer SB.

J Health Care Poor Underserved. 2015 Aug;26(3):811-23. doi: 10.1353/hpu.2015.0069.

31.

First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity.

Schijns VE, Pretto C, Devillers L, Pierre D, Hofman FM, Chen TC, Mespouille P, Hantos P, Glorieux P, Bota DA, Stathopoulos A.

Vaccine. 2015 May 28;33(23):2690-6. doi: 10.1016/j.vaccine.2015.03.095. Epub 2015 Apr 10.

32.

Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.

Bota DA, Alexandru-Abrams D, Pretto C, Hofman FM, Chen TC, Fu B, Carrillo JA, Schijns VE, Stathopoulos A.

Perm J. 2015 Spring;19(2):41-6. doi: 10.7812/TPP/14-042. Epub 2015 Mar 1.

33.

The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.

Paff M, Alexandru-Abrams D, Hsu FP, Bota DA.

Hum Vaccin Immunother. 2014;10(11):3322-31. doi: 10.4161/21645515.2014.983002. Review.

34.

Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma.

Abrams DA, Hanson JA, Brown JM, Hsu FP, Delashaw JB Jr, Bota DA.

J Clin Neurosci. 2015 Jan;22(1):35-9. doi: 10.1016/j.jocn.2014.05.054. Epub 2014 Dec 4. Review.

35.

Therapeutic targeting of malignant glioma.

Alexandru-Abrams D, Jadus MR, Hsu FP, Stathopoulos A, Bota DA.

Anticancer Agents Med Chem. 2014;14(8):1075-84. Review.

36.

Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models.

Di K, Keir ST, Alexandru-Abrams D, Gong X, Nguyen H, Friedman HS, Bota DA.

J Neurooncol. 2014 Dec;120(3):473-81. doi: 10.1007/s11060-014-1579-y. Epub 2014 Aug 13.

37.

Special medical conditions associated with catatonia in the internal medicine setting: hyponatremia-inducing psychosis and subsequent catatonia.

Novac AA, Bota D, Witkowski J, Lipiz J, Bota RG.

Perm J. 2014 Summer;18(3):78-81. doi: 10.7812/TPP/13-143.

38.

Two Patients With Brain Tumors Who Received Bevacizumab and Radiotherapy: Optic Neuropathy and Quality-of-Life Issues.

Fu DB, Alexandru D, Curticiu DM, Fu Y, Bota DA.

J Adv Pract Oncol. 2013 Jul;4(4):252-6. Review. No abstract available.

39.

Low-doses of cisplatin injure hippocampal synapses: a mechanism for 'chemo' brain?

Andres AL, Gong X, Di K, Bota DA.

Exp Neurol. 2014 May;255:137-44. doi: 10.1016/j.expneurol.2014.02.020. Epub 2014 Mar 2.

40.

Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme.

Hanson JA, Hsu FP, Jacob AT, Bota DA, Alexandru D.

Perm J. 2013 Fall;17(4):68-74. doi: 10.7812/TPP/13-081. Review.

41.

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.

J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.

42.

Risk factors for urinary tract infection with multiple drug-resistant Escherichia coli in cats.

Hernandez J, Bota D, Farbos M, Bernardin F, Ragetly G, Médaille C.

J Feline Med Surg. 2014 Feb;16(2):75-81. doi: 10.1177/1098612X13504407. Epub 2013 Sep 24.

PMID:
24065707
43.

Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article.

Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Lee JW, Kesari S.

J Neurosurg. 2013 Jun;118(6):1183-7. doi: 10.3171/2013.1.JNS12397. Epub 2013 Mar 1.

PMID:
23451905
44.

TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth.

Di K, Linskey ME, Bota DA.

Oncogene. 2013 Oct 17;32(42):5038-47. doi: 10.1038/onc.2012.531. Epub 2012 Nov 26.

45.

Glioma big potassium channel expression in human cancers and possible T cell epitopes for their immunotherapy.

Ge L, Hoa NT, Cornforth AN, Bota DA, Mai A, Kim DI, Chiou SK, Hickey MJ, Kruse CA, Jadus MR.

J Immunol. 2012 Sep 1;189(5):2625-34. doi: 10.4049/jimmunol.1102965. Epub 2012 Jul 27.

46.

SU-E-J-108: Quantitative Analysis of Longitudinal Cognitive Impairment Due to Radiation Therapy Based on Automatic Segmentation of Hippocampus and Subcortical Structure.

Lin Y, Chang D, Bota D, Roa D, Al-Ghazi M, Yu H, Kuo J, Nie K, Fwu P, Su M.

Med Phys. 2012 Jun;39(6Part7):3677. doi: 10.1118/1.4734944.

PMID:
28519814
47.

Epidemiology of central nervous system metastases.

Alexandru D, Bota DA, Linskey ME.

Prog Neurol Surg. 2012;25:13-29. doi: 10.1159/000331167. Epub 2012 Jan 6. Review.

PMID:
22236665
48.

Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.

Chamberlain MC, Bota DA, Linskey ME, Schwartz PH.

Neurology. 2011 Nov 29;77(22):e135; author reply e135-6. doi: 10.1212/WNL.0b013e318239ba7c. No abstract available.

49.

Impairment of lon-induced protection against the accumulation of oxidized proteins in senescent wi-38 fibroblasts.

Ngo JK, Pomatto LC, Bota DA, Koop AL, Davies KJ.

J Gerontol A Biol Sci Med Sci. 2011 Nov;66(11):1178-85. doi: 10.1093/gerona/glr145. Epub 2011 Aug 24.

50.

Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by ¹¹¹Indium-octreotide imaging.

Alexandru D, Glantz MJ, Kim L, Chamberlain MC, Bota DA.

Cancer. 2011 Oct 1;117(19):4506-11. doi: 10.1002/cncr.26065. Epub 2011 Mar 28.

Supplemental Content

Support Center